FY2026 EPS Estimate for Immuneering Lowered by Analyst

Immuneering Corporation (NASDAQ:IMRX) – Analysts at HC Wainwright decreased their FY2026 earnings estimates for shares of Immuneering in a research note issued on Friday, October 30th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($1.24) for the year, down from their prior forecast of ($1.10). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Immuneering’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Immuneering’s Q4 2026 earnings at ($0.39) EPS, Q1 2027 earnings at ($0.41) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.45) EPS, Q4 2027 earnings at ($0.48) EPS, FY2027 earnings at ($1.78) EPS, FY2028 earnings at ($1.87) EPS, FY2029 earnings at ($1.86) EPS and FY2030 earnings at ($0.81) EPS.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings data on Thursday, October 29th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.06).

A number of other equities research analysts also recently issued reports on the stock. Needham & Company LLC lifted their price target on shares of Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research note on Monday, September 21st. Cantor Fitzgerald initiated coverage on Immuneering in a report on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 price target on the stock. Chardan Capital raised Immuneering to a “strong-buy” rating in a research note on Monday, August 3rd. Finally, Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $15.67.

Immuneering Trading Down 6.7%

Shares of IMRX opened at $3.49 on Tuesday. The firm’s 50-day moving average is $4.25 and its two-hundred day moving average is $4.79. Immuneering has a twelve month low of $3.38 and a twelve month high of $8.48. The firm has a market capitalization of $225.79 million, a P/E ratio of -3.39 and a beta of 0.46.

Institutional Investors Weigh In On Immuneering

Several hedge funds have recently modified their holdings of IMRX. PVG Asset Management Corp acquired a new position in shares of Immuneering in the first quarter valued at approximately $773,000. Weiss Asset Management LP purchased a new position in shares of Immuneering during the first quarter valued at approximately $464,000. Corient Private Wealth LP purchased a new position in shares of Immuneering during the second quarter valued at approximately $385,000. Hsbc Holdings PLC purchased a new position in shares of Immuneering during the first quarter valued at approximately $198,000. Finally, WINTON GROUP Ltd acquired a new stake in Immuneering during the second quarter worth approximately $86,000. 67.65% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Immuneering

Here are the key news stories impacting Immuneering this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating, indicating the analyst continues to see long-term upside potential in Immuneering’s pipeline and business prospects.
• Positive Sentiment: Wall Street’s overall view remains constructive, with analysts rating the stock a “Moderate Buy.” Immuneering Corporation Stock Rated Moderate Buy by Wall Street Analysts
• Neutral Sentiment: HC Wainwright projected quarterly losses of $0.41 per share in Q1 2027, $0.43 in Q2, $0.45 in Q3 and $0.48 in Q4. The firm forecasts a full-year 2027 loss of $1.78 per share, followed by losses of $1.87 in 2028 and $1.86 in 2029.
• Negative Sentiment: HC Wainwright reduced its Q4 2026 loss estimate to $0.39 per share from $0.32 and lowered its FY2026 forecast to a $1.24 loss from $1.10. These revisions are worse than the current consensus estimate of a $1.09 full-year loss.
• Negative Sentiment: Longer-term estimates were also cut substantially: FY2027 to a $1.78 loss from $1.22, FY2028 to $1.87 from $1.30, FY2029 to $1.86 from $1.32, and FY2030 to an $0.81 loss from $0.40. The more pessimistic outlook likely contributed to the stock’s decline.

About Immuneering

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.

Immuneering’s lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.